Compare Gilead Sciences, Inc. (GILD) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Gilead Sciences, Inc.Trade

Vanguard S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Vanguard S&P 500 ETF — how do they compare? Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B), while Vanguard S&P 500 ETF trades at $710.06. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

	GILD	VOO
Market Cap	$168.35B	—
Sector	Health	Broad Market / Factor
52-Week High	$155.80	$710.71
52-Week Low	$110.56	$580.93
Enterprise Value	$191.42B	—
Dividend Yield	2.42%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

No Aura AI signal available yet.

Vanguard S&P 500 ETF

VOO (Vanguard S&P 500 ETF) trades at $710.71, up 0.6% with a bullish technical signal from moving averages. The ETF tracks the S&P 500 index, which recently reclaimed record highs amid strong corporate earnings and AI-driven optimism. Technical indicators show overbought conditions with RSI at 94.45 on the 6-day timeframe, while support levels begin at $708. JPMorgan raised its S&P 500 year-end target to 8,000, citing earnings strength and AI investment payoffs.

The outlook remains positive given robust earnings growth and institutional confidence, though near-term consolidation risks exist from overbought technicals and valuation concerns. Key risks include market breadth weakness and potential September volatility. The ETF's low-cost structure and diversification continue to attract long-term investors seeking S&P 500 exposure.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GILD

Gilead upgrades 2026 sales outlook as HIV drug Biktarvy and Livdelzi show strong growthSeeking Alpha · 2 days agoBullish 2026 National ORBIE Awards honor top CIOs and CISOs across key industry categories in San Jose.Inspire Leadership Network · 4 days agoNeutral View details →

VOO

Fidelity's zero-fee fund challenges Vanguard's S&P 500 ETF but offers limited gains for taxable accounts.24/7 Wall Street · 1 day agoNeutral Vanguard High Dividend Yield ETF lags S&P 500 by $141K over 10 years despite dividends.24/7 Wall Street · 1 day agoBearish Vanguard's S&P 500 ETF (VOO) offers cheaper, more flexible access than the mutual fund VFIAX.24/7 Wall Street · 2 days agoBullish View details →

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.